

October 17, 2019



# **NeuBase Therapeutics Announces Issuance of Foundational Patent Covering the Key Building Blocks of PATrOL™ Enabled Therapies**

PITTSBURGH, Oct. 17, 2019 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology company developing next-generation antisense therapies to address genetic diseases, today announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 10,370,415 covering the Company's proprietary DNA and RNA binding technology. This foundational patent enables PATrOL™-based therapies to target the secondary structures of DNA and RNA.

"The technology in this patent covers bi-specific nucleobases, which uniquely enables NeuBase to bind and manipulate the hard-to-reach double helix of the human genome and secondary structures of RNA," said Dietrich Stephan, Ph.D., chief executive officer of NeuBase Therapeutics. "The broad protection provided by the patent asserts our position as a leader in this field. This proprietary and modular technology will be used in conjunction with our peptide backbone technology to address a wide range of rare genetic diseases."

For more information about the NeuBase PATrOL platform and technology visit [neubasetherapeutics.com](http://neubasetherapeutics.com).

## **About NeuBase Therapeutics**

NeuBase Therapeutics, Inc. is developing the next generation of gene silencing therapies with its flexible, highly specific synthetic antisense oligonucleotides. The proprietary NeuBase peptide-nucleic acid (PNA) antisense oligonucleotide (PATrOL™) platform allows for the rapid development of targeted drugs, increasing the treatment opportunities for the hundreds of millions of people affected by rare genetic diseases, including those that can only be treated through accessing of secondary RNA structures. Using PATrOL technology, NeuBase aims to first tackle rare, genetic neurological disorders.

## **Use of Forward-Looking Statements**

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act. These forward-looking statements include, among other things, statements regarding the Company's goals and plans and expectations regarding the benefits of U.S. Patent No. 10,370,415. These forward-looking statements are distinguished by use of words such as "will," "would," "anticipate," "expect," "believe," "designed," "plan," or "intend," the negative of these terms, and similar references to future periods. These views involve risks and uncertainties that are difficult to predict and, accordingly, our actual results may differ materially from the results discussed in our forward-looking statements. Our forward-looking statements contained herein speak only as of the date of this press release. Factors or events that we cannot predict, including those risk factors contained in our filings

with the U.S. Securities and Exchange Commission, may cause our actual results to differ from those expressed in forward-looking statements. The Company may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements, and you should not place undue reliance on these forward-looking statements. Because such statements deal with future events and are based on the Company's current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of the Company could differ materially from those described in or implied by the statements in this press release, including: the Company's plans to develop and commercialize its product candidates; the timing of initiation of the Company's planned clinical trials; the timing of the availability of data from the Company's clinical trials; the timing of any planned investigational new drug application or new drug application; the Company's plans to research, develop and commercialize its current and future product candidates; the clinical utility, potential benefits and market acceptance of the Company's product candidates; the Company's commercialization, marketing and manufacturing capabilities and strategy; the Company's ability to protect its intellectual property position; and the requirement for additional capital to continue to advance these product candidates, which may not be available on favorable terms or at all, as well as those risk factors contained in our filings with the U.S. Securities and Exchange Commission. Except as otherwise required by law, the Company disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events or circumstances or otherwise.

**NeuBase Investor Contact:**

Dan Ferry  
Managing Director  
LifeSci Advisors, LLC  
[Daniel@lifesciadvisors.com](mailto:Daniel@lifesciadvisors.com)  
OP: (617) 535-7746

**NeuBase Media Contact:**

Travis Kruse  
Russo Partners  
[travis.kruse@russopartnersllc.com](mailto:travis.kruse@russopartnersllc.com)  
OP: (212) 845-4272

Ned Berkowitz  
Russo Partners  
[ned.berkowitz@russopartnersllc.com](mailto:ned.berkowitz@russopartnersllc.com)  
OP: (646) 942-5629

**neubase**

Source: NeuBase Therapeutics, Inc.